Quince Therapeutics

Formerly AI Therapeutics/LAM Therapeutics; acquired by Quince Therapeutics (Nasdaq: QNCX) 2026-05-18 alongside a $187M private placement -- recorded under parent's ticker

QNCX · Nasdaq · United States

Share price · QNCX

$31.73+14.24 (+81.42%) 3M

no price since 9 Oct 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when QNCX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Oct 2026+9.9%

    Nothing announced by QNCX that day or the session before.

  2. 18 Sep 2026+9.1%

    Nothing announced by QNCX that day or the session before.

  3. 25 Aug 2026-7.6%

    Nothing announced by QNCX that day or the session before.

  4. 29 Jul 2026+13.6%

    Nothing announced by QNCX that day or the session before.

  5. 28 Jul 2026+8.5%

    Nothing announced by QNCX that day or the session before.

  6. 14 Jul 2026+11.8%

    Nothing announced by QNCX that day or the session before.

  7. 10 Feb 2026+306.2%

    Nothing announced by QNCX that day or the session before.

  8. 30 Jan 2026-94.7%
  9. 16 Jan 2026+23.3%

    Nothing announced by QNCX that day or the session before.

  10. 26 Nov 2025+29.2%

    Nothing announced by QNCX that day or the session before.

Share of unusual movement by asset

For each asset, the share of QNCX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
LAM-001
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—87%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
mTOR (inhibitor)Small molecule
Pulmonary Hypertension Associated with Interstitial Lung DiseaseBronchiolitis Obliterans Syndrome

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$5.8M$40M+ $65M short-term inv.$28M-$9.8M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$5.5M$116M+ $0 short-term inv.$75M-$19M operating cash flowreport ↗
2026-Q1—$6.8M$18M—report ↗
2025-Q3—$8.1M$6.5M+ $20M short-term inv.$13M-$9.9M operating cash flowreport ↗
2025-Q2—$6.5M$17M+ $18M short-term inv.$16M-$11M operating cash flowreport ↗
2025-Q1—$8.2M$7.8M+ $24M short-term inv.$15M-$9.6M operating cash flowreport ↗
2024-Q3—$4.9M$2.7M+ $45M short-term inv.$5.5M-$7.3M operating cash flowreport ↗
2024-Q2—$4.2M$7.9M+ $52M short-term inv.$28M-$8.7M operating cash flowreport ↗
2024-Q1—$3.7M$22M+ $46M short-term inv.$11M-$8.3M operating cash flowreport ↗
2023-Q3—$1.4M$22M+ $62M short-term inv.$5.3M-$4.8M operating cash flowreport ↗
2023-Q2—$1.4M$23M+ $65M short-term inv.$4.9M-$3.8M operating cash flowreport ↗
2023-Q1—$3.2M$47M+ $43M short-term inv.$12M-$3.6M operating cash flowreport ↗
2022-Q3—$2.5M$32M+ $63M short-term inv.$7.9M-$6.7M operating cash flowreport ↗
2022-Q2—$7.2M$47M+ $48M short-term inv.$17M-$15M operating cash flowreport ↗
2022-Q1—$13M$68M+ $24M short-term inv.$22M-$16M operating cash flowreport ↗
2021-Q3—$14M$62M$22Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$35M$5.8M+ $12M short-term inv.$21M-$41M operating cash flowreport ↗

OrphAI Therapeutics reported R&D spend of $35.38M, up 90.3% YoY, cash and equivalents of $5.81M, and a net loss of $83.98M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$19M$6.2M+ $35M short-term inv.$14M-$32M operating cash flowreport ↗
2023-FY—$9.4M$21M+ $54M short-term inv.$7.8M-$18M operating cash flowreport ↗
2022-FY—$25M$45M+ $46M short-term inv.$13M-$44M operating cash flowreport ↗
2021-FY—$61M$70M+ $37M short-term inv.$22M-$63M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($174K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-09Militello John · Chief Financial OfficerAward / grant80,000——Form 4
2026-11-09Bonuccelli Catherine M. · directorAward / grant (derivative)17,000——Form 4
2026-11-09PATTERSON LEONE D · directorAward / grant (derivative)17,000——Form 4
2026-11-09Valentine James Elwood · directorAward / grant (derivative)17,000——Form 4
2026-11-09Wise John Drayton · directorAward / grant (derivative)17,000——Form 4
2026-06-11Senner Christopher J. · directorAward / grant (derivative)2,700——Form 4
2026-06-11Lamond David · directorAward / grant (derivative)2,700——Form 4
2026-05-18Roberts Brigette · director, Chief Corp. Affairs OfficerAward / grant (derivative)34,675——Form 4